Marinus Pharmaceuticals (MRNS)
(Real Time Quote from BATS)
$1.40 USD
-0.01 (-0.71%)
Updated Apr 19, 2024 03:16 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Marinus Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 150 | 241 | 123 | 140 | 92 |
Receivables | 4 | 6 | 3 | 2 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 5 | 6 | 5 | 2 |
Total Current Assets | 165 | 252 | 132 | 146 | 94 |
Net Property & Equipment | 4 | 4 | 3 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 3 | 3 | 2 | 2 |
Total Assets | 171 | 260 | 137 | 150 | 99 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 12 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 4 | 3 | 2 | 3 |
Current Portion Long-Term Debt | 2 | 1 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 23 | 20 | 16 | 9 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 21 | 0 | 0 |
Total Current Liabilities | 41 | 25 | 41 | 11 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 95 | 101 | 41 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 18 | 18 | 2 | 3 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 154 | 144 | 83 | 13 | 11 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 4 | 4 | 4 | 28 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 589 | 542 | 460 | 445 | 295 |
Retained Earnings | -572 | -431 | -411 | -312 | -236 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 17 | 116 | 53 | 137 | 88 |
Total Liabilities & Shareholder's Equity | 171 | 260 | 137 | 150 | 99 |
Total Common Equity | 17 | 112 | 49 | 133 | 60 |
Shares Outstanding | 54.50 | 49.60 | 36.70 | 30.50 | 20.50 |
Book Value Per Share | 0.31 | 2.26 | 1.34 | 4.35 | 2.91 |
Fiscal Year End for Marinus Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 150 | 176 | 175 | 199 |
Receivables | NA | 4 | 4 | 5 | 12 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 2 | 3 | 3 | 0 |
Other Current Assets | NA | 9 | 12 | 11 | 9 |
Total Current Assets | NA | 165 | 195 | 195 | 220 |
Net Property & Equipment | NA | 4 | 4 | 4 | 4 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 3 | 3 |
Total Assets | NA | 171 | 201 | 201 | 227 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 12 | 8 | 4 | 0 |
Accounts Payable | NA | 4 | 3 | 2 | 4 |
Current Portion Long-Term Debt | NA | 2 | 2 | 2 | 1 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 23 | 18 | 18 | 16 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 41 | 31 | 26 | 22 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 95 | 98 | 100 | 102 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 18 | 18 | 18 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 154 | 146 | 144 | 142 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 4 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 589 | 585 | 555 | 546 |
Retained Earnings | NA | -572 | -530 | -497 | -465 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 17 | 55 | 57 | 85 |
Total Liabilities & Shareholder's Equity | NA | 171 | 201 | 201 | 227 |
Total Common Equity | 0 | 17 | 55 | 57 | 81 |
Shares Outstanding | 54.90 | 54.50 | 50.60 | 50.50 | 49.60 |
Book Value Per Share | 0.00 | 0.31 | 1.08 | 1.14 | 1.63 |